Chalcogen Bonded Directly To The Hetero Ring Patents (Class 514/473)
  • Patent number: 10413520
    Abstract: The present invention relates to a pharmaceutical composition including (i) as a major ingredient, a novel 5-{4-(Aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone compound (Formula 1) or a pharmaceutically acceptable salt thereof, which has a crystalline form A or G, or a mixed form thereof and has a 50% volume particle diameter (d(0.5)) of 3 ?m to 9 ?m and a 90% volume particle diameter (d(0.9)) of 10 ?m to 50 ?m, (ii) a pharmaceutically acceptable diluent, and (iii) a pharmaceutically acceptable lubricant. The pharmaceutical composition of the present invention has the advantages of good stability, high dissolution rate, improved content uniformity, and excellent pharmacokinetic properties. Due to these advantages, as a non-steroidal anti-inflammatory drug, the pharmaceutical composition of the present invention may be effective in treating inflammation or pain.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: September 17, 2019
    Assignee: CRYSTALGENOMICS, INC.
    Inventors: Byung-Ha Kim, Sik II Ahn, Jae-Yeon Park, Tae Ryong Kim, Joong Myung Cho, Seonggu Ro
  • Patent number: 9943501
    Abstract: The present invention provides A PPAR? activator comprising a butenolide compound represented by the formula (1) or a pharmaceutically acceptable salt thereof: wherein R1 represents a hydrogen atom, a phosphate group, a fatty acid group, an alkyl group having 1 to 4 carbon atoms and optionally having a substituent or a sugar residue optionally having a substituent, and R2 represents a phenyl group, a methylphenyl group, a dimethylphenyl group, an ethylphenyl group, a benzyl group, a methylbenzyl group, a dimethylbenzyl group, an ethylbenzyl group, a phenethyl group, a methylphenethyl group, a dimethylphenethyl group, or an ethylphenethyl group.
    Type: Grant
    Filed: July 3, 2015
    Date of Patent: April 17, 2018
    Assignee: KOJUN JAPAN CO., LTD.
    Inventors: Bumbu Masutani, Yoshio Tsujino, Jiyeong An, Atsushi Yamatsu, Yusuke Yamashita, Seiyu Harada
  • Patent number: 9907852
    Abstract: The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: March 6, 2018
    Assignees: National University Corporation University of Toyama, Kracie Pharma, Ltd., National Cancer Center, Tokyo University of Science Foundation
    Inventors: Hiroyasu Esumi, Masafumi Ikeda, Katsuya Tsuchihara, Shigeki Chiba, Satoshi Yomoda, Takanori Kawashima, Toshiki Okubo, Yasuhiro Tezuka, Kenta Murata
  • Patent number: 9700572
    Abstract: The present invention is intended to provide a novel anticancer agent which is effective to a cancer. After administering an agent prepared using burdock fruit extract to a pancreas cancer patient so that a dose of arctigenin was 100 mg or more per day, the tumor reducing effect was observed, and, in addition, lowering of tumor markers was confirmed. The present invention provides an anticancer agent containing arctigenin, wherein a dose of the arctigenin is 100 mg or more per day. In addition, the present invention provides the anticancer agent containing arctigenin and arctiin at a weight ratio of arctigenin/arctiin=0.7 to 1.3.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: July 11, 2017
    Assignees: National Cancer Center, Kracie Pharma, Ltd., National University Corporation University of Toyama
    Inventors: Hiroyasu Esumi, Masafumi Ikeda, Chika Miyoshi, Shigetoshi Kadota, Toshiki Okubo, Satoshi Yomoda, Takafumi Fuse, Takanori Kawashima, Shigeki Chiba
  • Patent number: 9682111
    Abstract: Provided herein is a method for preventing or treating neurodegenerative disease in a subject, comprising administrating to the subject an effective amount of a composition which comprises a semen biotae extract. The neurodegenerative disease is associated with ?-synuclein, such as Alzheimer's disease, Parkinson's disease, Huntington disease, or Amyotrophic lateral sclerosis.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: June 20, 2017
    Inventors: Weiwei Su, Yonggang Wang, Fengyin Liang, Ning Wang, Zhong Pei, Haibin Liu
  • Patent number: 9480664
    Abstract: Compositions containing one or more COX inhibitors in combination with one or more antagonists of 20-HETE (20-hydroxyeicosatetraeonic acid), and optionally a pharmaceutically acceptable excipient are provided. Preferred compositions include rofecoxib in combination with HET0016. The compositions have reduced side effects due to COX inhibitors. Methods for treating or inhibiting cancer using the disclosed compositions are also provided.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: November 1, 2016
    Assignee: Augusta University Research Institute, Inc.
    Inventor: Mong-Heng Wang
  • Patent number: 9351915
    Abstract: An ascorbic acid derivative composition of a first aspect according to the present invention consists of a salt of a compound (1) represented by a general formula (1) shown below; and a salt of a compound (2) represented by a general formula (2) shown below, wherein a ratio of the salt of the compound (2) with respect to a total amount of the salt of the compound (1) and the salt of the compound (2) is from 0.1 to 10% by mass, wherein R1 represents a linear or branched alkyl group of 6 to 20 carbon atoms, R2 represents a linear or branched alkyl group of 6 to 20 carbon atoms, and R1 and R2 are the same or are different from each other.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: May 31, 2016
    Assignee: Showa Denko K.K.
    Inventors: Keiichi Nakamura, Takanori Aoki
  • Patent number: 9284194
    Abstract: An agent for reducing graphene oxide and a method for preparing reduced graphene oxide or graphene are provided. An agent for reducing graphene oxide include a mixture of a reducing agent containing a halogen element with trifluoroacetic acid (CF3COOH).
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: March 15, 2016
    Assignee: RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY
    Inventors: Hyoyoung Lee, Peng Cui
  • Patent number: 9192636
    Abstract: The present invention relates to compositions comprising Andrographis paniculata extracts combined with Ginkgo biloba extracts complexed with phospholipids. Moreover, the compositions administered in oils rich in ?-3 polyunsaturated fatty acids demonstrate a further synergic effect between the ingredients. Said compositions are useful in the treatment of neurodegenerative disorders, in particular Alzheimer's disease and multiple sclerosis.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: November 24, 2015
    Assignee: INDENA S.P.A.
    Inventors: Ezio Bombardelli, Andrea Giori
  • Patent number: 9162963
    Abstract: The invention provides novel phenylglyoxylic acid derivatives, which may be useful as intermediates for preparing stereoisomerically enriched drug compounds. The invention also provides methods of making phenylglyoxylic acid derivatives, and uses of phenylglyoxylic acid derivatives.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: October 20, 2015
    Assignee: vTv Therapeutics LLC
    Inventors: Dharma Rao Polisetti, Kalpathy Santhosh, Muralidhar Bondlela, Robert Carl Andrews, Thomas Scott Yokum, Eugene Campian, Rajashaker Kache
  • Patent number: 9085592
    Abstract: The present invention relates to process for the preparation of fosamprenavir calcium.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: July 21, 2015
    Assignee: RANBAXY LABORATORIES LIMITED
    Inventors: Satish Manohar Bhoge, Prakash Kshirsagar, Santosh Richhariya, Kaptan Singh
  • Patent number: 9073884
    Abstract: The invention provides novel compositions based on a structure designated as “Honaucin A”, including Honaucin A variants and analogs, and pharmaceutical compositions, liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these Honaucin A compounds, and variants and analogs thereof are used to ameliorate (including to treat or prevent) inflammation. In one embodiment, these Honaucin A compounds, and variants and analogs thereof are used to ameliorate (including to treat or prevent) inflammation. In one embodiment, these Honaucin A compounds, and variants and analogs thereof are used as bacterial quorumsensing inhibitors. Accordingly, in alternative embodiments the compositions of the invention are used as anti-bacterial agents.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: July 7, 2015
    Assignees: The Regents of the University of California, University of Rhode Island Research Foundation
    Inventors: William Gerwick, Lena Gerwick, Hyuakjae Choi, Francisco Villa, Jennifer Smith, David C Rowley
  • Patent number: 9060994
    Abstract: The effectiveness of interferon for treating multiple sclerosis and other demyelinating diseases is synergistically potentiated by concomitant administration of a compound of Formula (I): wherein R1 is H, alkyl or OH, R2 is hydroxyalkyl or alkyl-O-L1, R3 is H or OH, X is C(?CH2), CH(OH), or spirooxirane-2, Z is CH2CH(OH) or C(=0), and R4 is an optionally substituted L2-alkyl or L2-alkenyl, wherein L2 is an optionally substituted 3-furanyl or 3-fur-3-enyl moiety.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: June 23, 2015
    Assignee: Inno Biosciences, S.p.A.
    Inventors: Juan L Hancke Orozco, Rafael Burgos
  • Publication number: 20150148359
    Abstract: Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 28, 2015
    Inventors: Uri Ben-David, Nissim Benvenisty, Payal Arora, Qing-Fen Gan, Ralph J. Garippa
  • Publication number: 20150133406
    Abstract: Control or repellency of biting arthropods, particularly biting insects, is accomplished by bringing the biting arthropods into contact with combinations of compounds identical or related to those found on human/animal skin or in plants acting synergistically with one another, or in combination with conventional repellents like DEET®, para-menthane-3,8-diol (PMD), sec-butyl-2-(2-hydroxyethyl) piperidine carboxylate (“Picaridin”), or other nitrogen containing repellents selected from amines, amides and nitrogen containing heterocyclic compounds, or any synergistic combination of DEET®, PMD, Picaridin, or other nitrogen containing repellents selected from amines, amides and nitrogen containing heterocyclic compounds.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 14, 2015
    Inventor: Robert H. BEDOUKIAN
  • Publication number: 20150133540
    Abstract: Control or repellency of mosquitoes is accomplished by bringing the insects into contact with at least one of the compounds of the structure (I) wherein R is selected from —OH, ?O, —OC(O)R4, —OR6, —(OR6)2, wherein each R6 is independently selected from an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be ?O; each Z is independently selected from (CH) and (CH2); y is a numeral selected from 1 and 2; R1 is selected from H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; R2 is selected from H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms; R3 is selected from the group consisting of H and a branched or straight chain, satur
    Type: Application
    Filed: April 30, 2013
    Publication date: May 14, 2015
    Inventor: Robert H. Bedoukian
  • Patent number: 9029413
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, and in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. Antiviral activity of enzyme inhibitors is demonstrated.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: May 12, 2015
    Assignee: The Trustees of Princeton University
    Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
  • Publication number: 20150119458
    Abstract: The present invention discloses a 4-((substituted phenyl)difluoromethyl)phenoxycarboxylic acid derivative and preparation process and use thereof. More specifically, the present invention relates to a compound of the following formula I, which is defined in the specification. The compounds according to the present invention can be used as PPAR agonists, and demonstrates a strong effect on reducing the levels of total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) in blood plasma, and thus the compound according to the present invention can be used in the preparation of a medicament for treating or preventing hyperlipoidemia or cardio-cerebrovascular diseases caused by hyperlipoidemia, such as diabetes, atherosclerosis, stroke, coronary heart disease, etc. The present invention also relates to a novel intermediate compound for the preparation of the compound of formula I and preparation method thereof.
    Type: Application
    Filed: April 25, 2013
    Publication date: April 30, 2015
    Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Hua Bai, Jian Hong, Lifeng Cai, Hegeng Wei, Xiaoyu Liu, Xiaohe Zheng
  • Patent number: 9018251
    Abstract: Provided is a method for treating brain cancer or reducing temozolomide-resistance of brain cancer cells in a subject, comprising administrating to the subject an effective amount of an active ingredient selected from the group consisting of (Z)-butylidenephthalide of formula (I), a pharmaceutically acceptable salt of (Z)-butylidenephthalide, a pharmaceutically acceptable ester of (Z)-butylidenephthalide, and combinations thereof:
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: April 28, 2015
    Assignee: China Medical University
    Inventors: Horng-Jyh Harn, Shinn-Zong Lin, Tzyy-Wen Chiou, Po-Cheng Lin
  • Publication number: 20150110726
    Abstract: The present invention relates to novel uses of compounds from Antrodia cinnamomea mycelia and mixtures comprising the compounds. The novel uses comprise whitening skin, combating skin ageing, reducing scar formation, inducing or enhancing liver regeneration, or treating fibrosis or a fibrosis-associated disorder in a subject in need thereof. The compounds have the formula and preferably are selected from 3-isobutyl-4-[4-(3-methyl-2-butenyloxy)phenyl]furan-2,5-dione, 3-isobutyl-4-[4-(3-methyl-2-butenyloxy)phenyl]-1H-pyrrol-2,5-dione, 3-isobutyl-4-[4-(3-methyl-2-butenyloxy)phenyl]-1H-pyrrol-1-ol-2,5-dione, 3R*,4S*-1-hydroxy-3-isobutyl-4-[4-(3-methyl-2-butenyloxy)phenyl]pyrrolidine-2,5-dione, and 3R*,4R*-1-hydroxy-3-isobutyl-4-[4-(3-methyl-2-butenyloxy)phenyl]pyrrolidine-2,5-dione.
    Type: Application
    Filed: October 22, 2014
    Publication date: April 23, 2015
    Applicant: Simpson Biotech Co., Ltd.
    Inventors: Kai-Wen Huang, Chia-Chin Sheu
  • Patent number: 9012490
    Abstract: Compounds having formulas (I) to (VIII), salts thereof, or combinations thereof and pharmaceutical compositions comprising one or more these compounds are described herein for the treatment of HIV and neurodegenerative effects caused by HIV. Also provided herein are methods and a kit for inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia comprising administering the compounds having the formulas (I) to (VIII) and pharmaceutical compositions comprising the compounds having these formulas. The compounds having formulas I through VIII are curcumin analogs which are advantageously characterized as having anti-retroviral, neuroprotective, anti-glucosidase, and anti-HIV integrase properties. In one aspect, the pharmaceutical composition is delivered intranasally.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: April 21, 2015
    Assignee: Howard University
    Inventors: Evaristus A. Nwulia, Amol Kulkarni
  • Publication number: 20150105460
    Abstract: Provided in the present invention are various labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases. Also provided in the present invention is a semen biotae extract comprising one or more labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases.
    Type: Application
    Filed: June 4, 2012
    Publication date: April 16, 2015
    Inventors: Weiwei Su, Yonggang Wang, Fengyin Liang, Ning Wang, Zhong Pei, Haibin Liu
  • Publication number: 20150105459
    Abstract: The invention relates to the cosmetic use of a compound chosen from the compounds of formula (A) and the salts of same as an agent for depigmenting the skin and/or keratinous appendages.
    Type: Application
    Filed: April 18, 2013
    Publication date: April 16, 2015
    Inventors: Joel Boustie, Marie-Dominique Galibert-Anne, Francoise Lohezic-le Devehat, Marylene Chollet-Krugler, Sophie Tomasi, Nicolas Mouchet, Beatrice Legouin-Gardadennec
  • Publication number: 20150093338
    Abstract: There is provided compositions and methods for the treatment of respiratory conditions such as pulmonary hypertension and sickle-cell disease in a patient in need thereof. The composition and method are for treating a patient in need thereof by inhalation of a composition containing amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutical salts thereof.
    Type: Application
    Filed: October 8, 2014
    Publication date: April 2, 2015
    Inventor: Michael Farber
  • Publication number: 20150093345
    Abstract: An arctigenin derivative used for anti-aging treatment, including protection of the skin from the sun and recovery of skin elasticity. A variety of fatty acid ester derivatives, alcohol ether derivatives and alkylated derivatives are used as the arctigenin derivatives. Agents for controlling ET-1 production, elastase inhibitors, and anti-inflammatory agents are prepared. Such arctigenin derivatives are particularly useful as an external agent for the skin, such as an anti-inflammatory external agent, a sunscreen external agent, or an external agent for recovering elasticity.
    Type: Application
    Filed: March 27, 2013
    Publication date: April 2, 2015
    Inventors: Yuya Hayashi, Yoko Mizutare
  • Patent number: 8980795
    Abstract: Novel compounds of formula (I) their use as germination trap for parasitic weeds, for the regulation of branching, tillering and root development, for enhancement of cambium growth, for the regulation of hyphal growth of mycorrhizal fungi and compositions comprising compounds of formula (I) and insecticides and/or fungicides.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: March 17, 2015
    Assignee: King Abdullah University of Science and Technology
    Inventors: Salim Al-Babili, Adrian Alder
  • Patent number: 8969408
    Abstract: The present invention relates to a new use of lignan-type compounds or an extract of nutmeg or aril of nutmeg comprising the same. More particularly, the present invention relates to a composition for skin whitening comprising a lignan-type compound or an extract of nutmeg or aril of nutmeg comprising the same. Because the lignan compound represented by Chemical Formulas 1 to 3 or the extract of nutmeg or aril of nutmeg has superior skin whitening activity by inhibiting melanin production and tyrosinase activity, it can be used for the preparation of a cosmetic composition, food composition or pharmaceutical composition for skin whitening.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: March 3, 2015
    Assignees: Biocare Co., Ltd., Newtree Co., Ltd.
    Inventors: Jae Kwan Hwang, Yu-Mi Cho, Gyu Hoi Kim, Jeong Hwan Kim, Hae Ji Lee, Do Un Kim, Hee Chul Chung, Jae Youn Chung, Hyun In Oh
  • Publication number: 20150056300
    Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.1 to about 40 weight percent of a therapeutic agent and about 10 to about 90 weight percent a diblock poly(lactic) acid-poly(ethylene)glycol copolymer or a diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer, wherein the diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic) acid having a number average molecule weight of about 30 kDa to about 90 kDa or the diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer comprises poly(lactic)-co-poly(glycolic) acid having a number average molecule weight of about 30 kDa to about 90 kDa.
    Type: Application
    Filed: October 24, 2011
    Publication date: February 26, 2015
    Applicant: BIND Therapeutics, Inc.
    Inventors: David Dewitt, Maria Figueiredo, Hong Wang, Greg Troiano, Young-Ho Song
  • Publication number: 20150051276
    Abstract: Compounds are used as agents that deter feeding of crops by agricultural pests such as hemiptera, lepidoptera and coleoptera, including, but not limited to, stink bugs, codling moth larvae and granary weevils.
    Type: Application
    Filed: April 30, 2013
    Publication date: February 19, 2015
    Inventor: Robert H. Bedoukian
  • Publication number: 20150051278
    Abstract: The invention is a method of exterminating a harmful insect with an agricultural and horticultural insecticide containing one or more kinds of compound (A) selected from a specific polyoxyethylene fatty acid ester, a specific polyoxyethylene sorbitan fatty acid ester, a specific (poly)glycerol fatty acid ester, and a specific alkyl saccharide, and a compound (B) of an alcohol having a linear or branched alkyl group having 8 to 14 carbon atoms or a linear or branched alkyl ether having 6 to 12 carbon atoms, provided that an agricultural chemical ingredient of an agricultural chemical is not substantially contained.
    Type: Application
    Filed: February 25, 2013
    Publication date: February 19, 2015
    Inventor: Masatoshi Kamei
  • Patent number: 8952062
    Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: February 10, 2015
    Assignee: Jazz Pharmaceuticals, Inc.
    Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
  • Patent number: 8946153
    Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises levan.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: February 3, 2015
    Assignee: Ferring B.V.
    Inventors: Shweta Gupta, Varinder Ahuja, Tejas Gunjikar, Kristin Wannerberger
  • Patent number: 8946280
    Abstract: The present invention relates to novel strigolactam derivatives of formula (I) to processes and intermediates for preparing them, to plant growth regulator compositions comprising them and to methods of using them for controlling the growth of plants and/or promoting the germination of seeds.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: February 3, 2015
    Assignee: Syngenta Participations AG
    Inventors: Mathilde Denise Lachia, Alain De Mesmaeker, Hanno Christian Wolf, Pierre Joseph Marcel Jung
  • Publication number: 20150030577
    Abstract: Provided are compounds and compositions derived from Pseudomonas sp., particularly, Pseudomonas fluorescens or Pseudomonas protegens and more particularly strain having the identifying characteristics of Pseudomonas ATCC 55799 having antimicrobial properties and particularly, antibacterial properties.
    Type: Application
    Filed: February 27, 2013
    Publication date: January 29, 2015
    Applicant: Marrone Bio Innovations, Inc.
    Inventors: Ratnakar Asolkar, Ana Lucia Cordova-Kreylos, Carly Todd
  • Publication number: 20150030579
    Abstract: Hydroxytyrosol or olive juice containing hydroxytyrosol in combination with at least one of the compounds selected from the group consisting of: creatine, coenzyme Q10, resveratrol, caffeine, carnitine, B vitamins (B1, B2, B3, B5, B6, and/or B12) and ginseng (preferably: root) extract. can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue.
    Type: Application
    Filed: August 1, 2014
    Publication date: January 29, 2015
    Applicant: DSM IP ASSETS B.V.
    Inventors: Ann FOWLER, Angelika FRIEDEL, Darko KNUTTI, Karin KURATLI, Daniel RAEDERSTORFF, Ying WANG-SCHMIDT, Karin WERTZ
  • Publication number: 20150025069
    Abstract: This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 22, 2015
    Inventors: Timothy Scott Daynard, Geoffrey C. Winters, David W.C. Hunt
  • Publication number: 20150025135
    Abstract: The present invention provides methods and compositions for treating leukemia by cyclohexenone compounds.
    Type: Application
    Filed: February 20, 2014
    Publication date: January 22, 2015
    Applicant: Golden Biotechnology Corporation
    Inventors: Sheng-Yung Liu, Wu-Che Wen, Chih-Ming Chen
  • Publication number: 20150017218
    Abstract: A wet wipe includes a cleansing composition and a substrate. The cleansing composition includes a preservative enhancing agent selected from the group consisting of caprylyl glycol; caprylyl glyceryl ether; glyceryl caprylate; sorbitan caprylate; ethylhyexyl glycerin, and combinations thereof. The cleansing composition includes a preservative selected from the group consisting of benzoic acid; lactic acid; sorbic acid; malic acid; maleic acid, and combinations thereof. The cleansing composition has a pH less than about 4. A method of making the cleansing composition may include dissolving one or more preservatives with water to form a solution; adding a rheology modifier to the solution; adding an emulsifier to the solution; adding a preservative enhancing agent to the solution; and adding citric acid to the solution.
    Type: Application
    Filed: July 14, 2014
    Publication date: January 15, 2015
    Inventors: Charles Allen PETTIGREW, Justin Angelo CASERTA, Donna Jane WIEDEMANN
  • Publication number: 20150017099
    Abstract: The invention provides methods and compositions for the diagnosis, prognosis and treatment of respiratory tract diseases. Specifically, the invention provides diagnosis, prognosis and treatment of respiratory infections using bitter and sweet taste signal transduction pathways. In one aspect, the invention relates to a method for treating a respiratory infection by administering a composition to the respiratory tract of a subject in an amount capable of activating bitter taste signaling and/or inhibiting sweet taste signaling. The composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract. In another aspect, the invention relates to a composition for treatment of a respiratory infection. Such composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract.
    Type: Application
    Filed: January 25, 2013
    Publication date: January 15, 2015
    Inventors: Noam A. Cohen, Robert J. Lee, Danielle R. Reed
  • Publication number: 20150010636
    Abstract: A method for inhibiting formation of adhesions following abdominal surgery which involves application of an anti-static fatty acid ethoxylated amide (Cocamide DEA) in a matrix that is placed in the peritoneal cavity at the conclusion of an abdominal surgery and which releases this anti-adhesive chemical over a predetermined time in a range up to seven days. Tests conducted on laboratory rats established that the method reduced the incidence of adhesions from 100 percent (100%) in a test model to near zero in the majority of treated animals. In an alternative embodiment, andrographalide was delivered via a pump with similar results. In still another embodiment, an effective amount of 50% phosphatidylchorene and propylene glycol was delivered, via a pump, into the abdominal cavity, again with similar results.
    Type: Application
    Filed: September 10, 2014
    Publication date: January 8, 2015
    Applicant: ANHESE LLC
    Inventor: John P. Delaney
  • Patent number: 8921417
    Abstract: A method for treatment and or/prevention of dyslipidemia is provided. The invention relates to reducing low density lipoprotein cholesterol concentration by using naturally occurring diterpene (16?-hydroxycleroda-3,13(14)Z-dien-15,16-olide, a compound having formula (1)) isolated from leaves of Polyalthia longifolia.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: December 30, 2014
    Assignee: Council of Scientific & Industrial Research
    Inventors: Koneni Venkata Sashidhara, Anju Puri, Jammikuntla Naga Rosaiah
  • Publication number: 20140356458
    Abstract: The present invention includes embodiments for treatment and/or prevention of sickle cell disease that employ Hydroxyfasudil or Isocoronarin D alone or either in conjunction with each other or an inducer of HbF production. The compounds may act synergistically, and the compounds employed circumvent the side effects seen with Hydroxyurea.
    Type: Application
    Filed: September 13, 2012
    Publication date: December 4, 2014
    Applicant: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Magbubah Essack, Vladimir Bajic, Aleksandar Radovanovic
  • Patent number: 8901038
    Abstract: The invention relates to novel compounds of the formula (I) in which W, X, Y, Z, and CKE have the meanings given above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides and/or fungicides. Moreover, the invention relates to selectively herbicidal compositions comprising, firstly, the biphenyl-substituted cyclic ketoenols and, secondly, a crop plant compatibility-improving compound. The present invention furthermore relates to the boosting of the action of crop protection compositions comprising in particular biphenyl-substituted cyclic ketoenols through the addition of ammonium or phosphium salts and optionally penetrants, to the corresponding compositions, to processes for their preparation and to their use in crop protection as insecticides and/or nematicides and/or acaricides and/or fungicides and/or for preventing unwanted plant growth.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: December 2, 2014
    Assignee: Bayer CropScience AG
    Inventors: Reiner Fischer, Stefan Lehr, Isolde Häuser-Hahn, Christopher Hugh Rosinger, Chieko Ueno, Arnd Voerste, Elmar Gatzweiler, Ines Heinemann, Ulrich Görgens
  • Patent number: 8884034
    Abstract: This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: November 11, 2014
    Assignee: Dermira (Canada), Inc.
    Inventors: Timothy Scott Daynard, Geoffrey C. Winters, David W. C. Hunt
  • Publication number: 20140323561
    Abstract: Control and repellency of biting flies, house flies, ticks, ants, fleas, biting midges, cockroaches, spiders and stink bugs is obtained by contact of the insects with at least one of the compounds of the structure (I).
    Type: Application
    Filed: October 21, 2013
    Publication date: October 30, 2014
    Inventor: Robert H. Bedoukian
  • Publication number: 20140315846
    Abstract: An extract of Andrographis paniculata extract containing androgapholide, 14-deoxyandrographolide, 14-deoxy-11,12-dehydroandrographolide, neoandrographolide, polysaccharides, and flavanoids. Also disclosed is a pharmaceutical composition containing such an extract and its use for treating inflammatory bowel disease.
    Type: Application
    Filed: July 1, 2014
    Publication date: October 23, 2014
    Inventors: Jifeng DUAN, Zhiming MA, Xiaoqiang YAN, Weihan ZHANG, Tao WANG, Yu CAI
  • Publication number: 20140308379
    Abstract: The invention provides compositions and methods for treating neurological disorders and viral infection using whole-grain flaxseed, flaxseed lignans such as Secoisolariciresinol diglucoside (SDG), human lignans metabolized from flaxseed such as Enterodiol (ED) or Enterolactone (EL), and synthetic flaxseed lignan analogs.
    Type: Application
    Filed: November 19, 2013
    Publication date: October 16, 2014
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Melpo CHRISTOFIDOU-SOLOMIDOU, Kelly JORDAN-SCIUTTO
  • Patent number: 8859619
    Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: October 14, 2014
    Assignee: Jazz Pharmaceuticals, Inc.
    Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
  • Publication number: 20140287924
    Abstract: Novel compounds of formula (I) their use as germination trap for parasitic weeds, for the regulation of branching, tillering and root development, for enhancement of cambium growth, for the regulation of hyphal growth of mycorrhizal fungi and compositions comprising compounds of formula (I) and insecticides and/or fungicides.
    Type: Application
    Filed: April 25, 2012
    Publication date: September 25, 2014
    Inventors: Salim Al-Babili, Adrian Alder
  • Patent number: 8841294
    Abstract: The invention relates to insecticidal and acaricidal mixtures comprising certain cyclic ketoenols and agonists or antagonists of nicotinic acetylcholine receptors for protecting plants against attack by pests.
    Type: Grant
    Filed: January 6, 2005
    Date of Patent: September 23, 2014
    Assignee: Bayer Cropscience AG
    Inventors: Reiner Fischer, Christoph Erdelen